[1] Coats AJS, Shewan LG. Statement on authorship and publishing ethics in the international journal of cardiology. Int J Cardiol 2011;153:239–40. [2] Cleland JGF, Daubert J-C, Erdmann E, et al. The Cardiac Resynchronization‐Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–49. [3] Kubanek M, Malek I, Bytesnik J, et al. Decrease in plasma B-type natriuretic peptide early after cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 2006;8:832–40. [4] Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721–6. [5] de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811–7. [6] McMurray J, ChopraM, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493–8. [7] Lopez-Andres N, Rossignol P, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012;14(1):74–81. [8] Hendrichova M, Malek F, Kopřivova H, et al. Correlation of NT-proBNP with metabolic liver function as assessed with C‐methacetin breath test in patients with acute decompensated heart failure. Int J Cardiol 2010;144(2):321–2.